engleski

Direct-Acting Antivirals (DAAs): Drug-Drug Interactions (DDIs) in the Treatment of Hepatitis C Virus (HCV)

Hepatitis C virus (HCV)-infected patients often use multiple medications to treat infection, adverse events related to HCV therapy, or to manage other comorbidities. Drug-drug interactions (DDIs) associated with this polypharmacy are important in HCV pharmacotherapy, especially after introduction of direct-acting antivirals (DAAs). Knowledge about pharmacokinetics, metabolism, and disposition of drugs used in the treatment of HCV and comorbidities is crucial in the interpretation of these data and management of these interactions (e.g. dose adjustments, therapeutic drug monitoring, or safe alternatives). Web-based DDIs interactive tools like http://www.hep-druginteractions.org represent the most feasible and comprehensive way for an assessment of potential DDIs before, during, and after treatment. Additional helpful resources are data from clinical drug interaction studies as well as recent real-life data. This chapter is practical overview of DDIs in the treatment of HCV with the last update.

hepatitis C virus, direct-acting antivirals, drug-drug interactions, cytochrome P450, antiviral therapy

nije evidentirano